RnRMarketResearch.com adds “Investigation Report on China Insulin Aspart Market, 2010-2019”to its store.
According to a report issued by WHO in 2014, the incidence of diabetes was estimated to be 9% among adults aged above 18 in the world. In 2012, diabetes reported an estimated 1.5 million cases of death, among which over 80% were in middle income and low income countries. And WHO made a prediction that diabetes will become the seventh leading cause of death by 2030. A nationwide diabetes survey carried out in 2010 in China showed that 11.6% of adults, that is 114 million people, suffered from diabetes and that the incidence of diabetes was 12.1% in men and 11% in women. And China has surpassed the US to become the country with the largest number of diabetes case.
Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast-acting insulin analog, starts working fast and reports higher peak of glucose-lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted.
Insulin aspart develops fast after entering China. Its sales value reached CNY 336 million in 2013 and CNY 380 million in 2014 with a year-on-year increase of 13.10% while its sales volume reached 4.42 million in 2013 and 5.01 million in 2014, increasing 13.35% year on year. With economic development and lifestyle changes, the incidence of diabetes in China will keep going up, which fosters the huge demand for insulin aspart. Currently, the market is dominated by Novo Nordisk (Denmark) and Novo Nordisk (China), the former enjoying a larger market share of 100% with sales value reaching nearly CNY 380 million in 2014. As some local enterprises are trying to make generic drugs of insulin aspart, the monopoly of Novo Nordisk is expected to be broken by local products in the next few years.
Complete report available @ http://www.rnrmarketresearch.com/investigation-report-on-china-insulin-aspart-market-2010-2019-market-report.html .
Readers can get at least the following information through this report:
- diabetes incidence in China
- market share of insulin aspart manufacturers in sample hospitals in China
- price of insulin aspart in Chinese hospitals
- production of generic drugs of insulin aspart in China
- major manufacturers of insulin aspart in China
- share of different dosage forms of insulin aspart in Chinese hospitals
- market outlook of insulin aspart in China
The author suggests the following groups of people purchase this report:
- manufacturers of antidiabetic drugs
- medical institution
- investors/ research institutions interested in Chinese medicine market
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=397508 .
Table of Contents
1 Related Concepts of Insulin Aspart
1.2 Sales Status in Global Market
2 Market Profile of Insulin Aspart in China
2.1 Patent Status and Approval Information of Insulin Aspart in China
2.2 Major Manufacturers
2.3 Market Size
3 Survey on Insulin Aspart Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 Survey on Market Share of Major Manufacturers of Insulin Aspart in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Survey on Dosage Forms of Insulin Aspart in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume